Ta grade 3/high grade non‐invasive bladder cancer: Should we perform a second TUR?

2020 ◽  
Author(s):  
Ilker Tinay ◽  
Sumer Baltaci ◽  
Cetin Demirdag ◽  
Bulent Akdogan ◽  
Ugur Yucetas ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Invasive Bladder Cancer ◽  
High Grade ◽  
Non Invasive ◽  
Second Tur ◽  
Grade 3

Bladder cancer

2017 ◽  
Author(s):  
Richard P. Meijer ◽  
Alexandre R. Zlotta ◽  
Bas W.G. van Rhijn
Keyword(s):  
Bladder Cancer ◽  
High Specificity ◽  
Invasive Bladder Cancer ◽  
Urinary Cytology ◽  
High Grade ◽  
Muscle Invasive Bladder Cancer ◽  
Non Invasive ◽  
Important Diagnostic Tool ◽  
Moderate Sensitivity ◽  
Muscle Invasive

High-grade non-muscle-invasive bladder cancer (HG-NMIBC) represents the most aggressive spectrum of this non-invasive cancer. This collective term includes all high-grade NMI urothelial carcinoma (UC), such as those without invasion (pTa), those with lamina propria invasion (pT1), and those that are only/have concomitant carcinoma in situ (CIS; pTis). These cancers have a high risk for intravesical recurrence (around 46–78% at five years) and progression (between 6–45% at five years) to muscle-invasive bladder cancer (MIBC). As with all UC, their presentation can be with visible haematuria or irritative lower urinary tract symptoms. The latter are common in patients with CIS. CIS may be detected in isolation (so-called primary CIS) or with a coexisting UC elsewhere (termed concomitant CIS). While urinary cytology has a moderate sensitivity and high specificity (>90%) for the detection of HG-NMIBC, cystoscopy is the most important diagnostic tool.

Comprehensive targeted gene profiling to determine the genomic signature likely to drive progression of high-grade nonmuscle invasive bladder cancer to muscle invasive bladder cancer.

2020 ◽  
Vol 38 (6_suppl) ◽  
pp. 568-568
Author(s):  
Abedalrhman Alkhateeb ◽  
Govindaraja Atikukke ◽  
Lisa Porter ◽  
Bre-Anne Fifield ◽  
Dora Cavallo-Medved ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Gene Profiling ◽  
Invasive Bladder Cancer ◽  
Low Grade ◽  
Genomic Profiling ◽  
High Grade ◽  
Single Nucleotide Variants ◽  
Muscle Invasive Bladder Cancer ◽  
Non Invasive ◽  
Muscle Invasive

568 Background: Bladder cancer is the fifth most common cancer and eighth leading cause of cancer related-death in North America. It can present as non-muscle invasive bladder cancer (NMIBC) and/or muscle invasive bladder (MIBC). Although genomic profiling studies have established that low-grade NMIBC and MIBC are genetically distinct, high-grade NMIBC can recur and progress to MIBC [ Knowles, M.A. and C.D. Hurst, 2015]. Low grade, non-invasive bladder cancers are characterized by activating mutations in fibroblast growth factor receptor 3 (FGFR3), HRAS or other pathways of receptor kinase activation. High-grade disease, which is often becomes invasive, is characterized by inactivation of TP53 and Rb pathways [Kim, J., et al.]. Finding a subtype of invasive carcinoma with FGFR3 mutation may suggest an alternate pathway by which low grade, non-invasive pathology could transform into invasive disease [Knowles, M.A. and C.D. Hurst, 2015]. Methods: In this study, using a total of 30 bladder cancer (NMIBC and MIBC) patient samples from Windsor Regional Hospital Cancer Program, we performed comprehensive targeted gene sequencing to identify single nucleotide variants, small insertions / deletions, copy number variants and splice variants in over 500 common tumor genes panel. Results: Preliminary data from our study correlates with previously published mutation landscape for NMIBC and MIBC, and includes mutations in EGFR, FGFR3, FGFR4, PIK3CA, CDK6, ALK, JAK, as well as RET. While mutations in AKT1, BRCA1, CCND1, ERBB2, FGFR1, FGFR2, HRAS, and MET appear to be prevalent in NMIBC, mutations in IDH1 and MAP2K2 appear to be more common in MIBC. Three of the samples used in the study are from patients who progressed from high-grade NMIBC to MIBC. Conclusions: Therefore, have the genomic profiling performed at these two stages, which provides a unique ability to identify the potential “genomic triggers” for the transition.

scholarly journals Methylation of HOXA9 and ISL1 Predicts Patient Outcome in High-Grade Non-Invasive Bladder Cancer

PLoS ONE ◽  
2015 ◽  
Vol 10 (9) ◽  
pp. e0137003 ◽  
Author(s):  
Mark O. Kitchen ◽  
Richard T. Bryan ◽  
Kim E. Haworth ◽  
Richard D. Emes ◽  
Christopher Luscombe ◽  
...  
Keyword(s):  
Patient Outcome ◽  
Bladder Cancer ◽  
Invasive Bladder Cancer ◽  
High Grade ◽  
Non Invasive

646 SECOND-TUR OF INITIAL HIGH GRADE T1 BLADDER CANCER AFTER-BCG AND ACCORDING TO LAMINA PROPRIA INVASION MICROSTAGING (T1 A/B)

2009 ◽  
Vol 8 (4) ◽  
pp. 282 ◽  
Author(s):  
Busquets C.X. Raventos ◽  
A. Orsola ◽  
L. Cecchini ◽  
E. Trilla ◽  
J. Planas ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Lamina Propria ◽  
High Grade ◽  
Second Tur
Sign in / Sign up

Export Citation Format

Share Document